🇪🇺 Pharmacologic Stress Agent in European Union

EMA authorised Pharmacologic Stress Agent on 6 September 2010

Marketing authorisation

EMA — authorised 6 September 2010

  • Application: EMEA/H/C/001176
  • Marketing authorisation holder: GE Healthcare AS
  • Local brand name: Rapiscan
  • Indication: This medicinal product is for diagnostic use only. Rapiscan is a selective coronary vasodilator for use as a pharmacological stress agent for radionuclide myocardial perfusion imaging (MPI) in adult patients unable to undergo adequate exercise stress.
  • Status: approved

Read official source →

Pharmacologic Stress Agent in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Pharmacologic Stress Agent approved in European Union?

Yes. EMA authorised it on 6 September 2010.

Who is the marketing authorisation holder for Pharmacologic Stress Agent in European Union?

GE Healthcare AS holds the EU marketing authorisation.